BYSI (BeyondSpring) Marketable Securities: $3.83 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BYSI BeyondSpring Inc BYSI
25 GF Score
Price $1.26
! 1 Warning Sign
View Full Analysis

What is BeyondSpring Marketable Securities?

BeyondSpring BYSI +1.21% 25 Marketable Securities is $3.83 Mil as of Mar. 2026. GuruFocus rates BYSI with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. BeyondSpring's Marketable Securities for the quarter that ended in Mar. 2026 was $3.83 Mil.

BeyondSpring's annual Marketable Securities stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($4.78 Mil).

BeyondSpring  (NAS:BYSI) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

BeyondSpring Marketable Securities Related Terms

BeyondSpring Marketable Securities Historical Data

* Premium members only.

The historical data trend for BeyondSpring's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeyondSpring Marketable Securities Chart

BeyondSpring Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.74 2.87 0.00 0.00 4.78

BeyondSpring Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 0.00 0.14 4.78 3.83
BYSI
25GF Score
BeyondSpring Inc BYSI
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeyondSpring Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $3.83 Mil mean?
BeyondSpring (BYSI) has a Marketable Securities of $3.83 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BeyondSpring and its competitors.
Is BeyondSpring's Marketable Securities too high?
BeyondSpring's current Marketable Securities is $3.83 Mil. Overall, BeyondSpring has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BeyondSpring's Marketable Securities compare to PLRX and MCRB?
BeyondSpring's Marketable Securities of $3.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BeyondSpring and its competitors. BeyondSpring's current Marketable Securities is $3.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeyondSpring stock overvalued right now?
BeyondSpring (BYSI) has a current Marketable Securities of $3.83 Mil. The current Marketable Securities is $3.83 Mil. BeyondSpring's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For BeyondSpring (BYSI), the current Marketable Securities is $3.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BeyondSpring Business Description

Address 100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, New Jersey, NJ, USA, 07932
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
25GF Score

Get the complete analysis for BYSI

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price